Montana’s new legislation, championed by longevity enthusiasts and policymakers, allows licensed medical clinics to administer and sell unapproved anti-aging therapies that have completed only phase I clinical trials, expanding right-to-try beyond terminal patients. The law creates an annual licensing framework, informed consent requirements, and protections for prescribing physicians to foster a domestic hub for experimental longevity research and medical tourism.
Key points
Permits licensed clinics to sell senolytic and gene therapies post-phase I trials without full FDA approval
Introduces annual licensing, enhanced informed consent, and legal protections for providers under expanded Right to Try provisions
Requires in-state drug manufacturing, profit-sharing for local healthcare, and aims to establish Montana as a medical tourism hub
Why it matters:
This law shifts drug-approval norms by granting early patient access to experimental anti-aging therapies, potentially accelerating longevity research.
Q&A
What is a phase I clinical trial?
What are senolytic therapies?
What does Right to Try mean under this law?
What informed consent safeguards are required?
Read full article
Academy
Experimental Treatments and Regulatory Frameworks in Longevity Science
Overview: Understanding the regulatory environment is crucial for appreciating how experimental treatments progress from lab to clinic. In longevity science, regulatory frameworks balance patient safety with the need for innovation to address age-related diseases.
Right to Try Laws
Right to Try laws permit patients with serious or life-threatening conditions to access investigational drugs that have passed phase I safety studies but lack full approval. These statutes emerged to give patients early access to therapies when no alternatives exist. Montana’s new law extends this right to all residents and treatments aimed at slowing or reversing aging, moving beyond terminal illness scenarios.
Clinical Trial Phases
Drug development typically involves three main clinical phases:
- Phase I: Safety assessment in a small group of healthy volunteers or patients.
- Phase II: Efficacy evaluation and dosage optimization in a larger cohort.
- Phase III: Confirmation of efficacy and monitoring of adverse effects in broad populations.
Senolytic and gene therapies often start with phase I trials to check safety before progressing to larger studies.
Senolytic Therapies
Senolytics are agents that selectively remove senescent cells, which accumulate with age and contribute to chronic inflammation and tissue dysfunction. By targeting pathways such as Bcl-2 or PI3K/AKT, these therapies aim to rejuvenate tissues, reduce disease risk, and extend healthspan. Preclinical models show that clearance of senescent cells improves function in organs like the heart and kidneys.
Informed Consent Requirements
Enhanced informed consent ensures that patients receive full disclosure about:
- The experimental nature of treatments and phase I safety-only data.
- Potential risks, including unknown long-term effects.
- Available alternative approved therapies.
- Worst-case scenario outcomes.
This process upholds ethical standards and empowers patient decision-making in experimental settings.
In-State Manufacturing and Medical Tourism
Montana’s requirement for local drug production leverages existing biotech facilities to streamline supply chains and reduce regulatory hurdles. Coupled with profit-sharing mandates to support resident healthcare, the state positions itself as a domestic hub for medical tourism, attracting patients seeking experimental longevity interventions while boosting local economies.